The effects of olmesartan on ambulatory blood pressures and blood pressure variability in patients with mild to moderate essential hypertension
10.3760/cma.j.issn.0578-1426.2014.10.007
- VernacularTitle:奥美沙坦酯对轻、中度原发性高血压患者的降压疗效及血压变异的影响
- Author:
Jing LI
;
Tingli QIN
;
Hong JIANG
;
Hao WANG
;
Yuannan KE
- Publication Type:Journal Article
- Keywords:
Hypertension;
Olmesartan;
Ambulatory blood pressure monitoring;
Blood pressure variability
- From:
Chinese Journal of Internal Medicine
2014;53(10):788-792
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effect of olmesartan medoxomil tablets (olmesartan) in comparison with Olmetec on 24 h ambulatory blood pressure (ABPM) and blood pressure variability (BPV)in patients with mild to moderate hypertension.Methods A randomized,double-blind,double-mimic controlled trial was performed.Forty-eight patients with mild to moderate essential hypertension were randomly into treatment group (olmesartan) and control group (Olmetec) for eight weeks.The ABPM was taken before and at the end of the trial.Results After eight weeks,treatment with olmesartan induced a significant reduction in ABPM in patients [(9 ± 3)/(11 ± 3) mmHg (1 mmHg =0.133 kPa)],which is similar with the reduction by Olmetec [(9 ± 4) / (9 ± 5) mmHg],P ＞ 0.05.This situation holds for BPV with the standard deviations of 24 h,systolic blood pressure/diastolic blood pressure of pre-treatment and pro-treatment were (10 ± 2)/(11 ± 3) mmHg vs (10 ± 3)/(12 ± 2) mmHg in olmesartan group,and (10 ± 3)/(11 ±3) mmHg vs (12 ±3)/(12 ±4) mmHg in Olmetec group.(3) There is no difference in the rate of adverse event between olmesartan (10.42％) and Olmetec (8.33％) treatment(P ＞ 0.05).Conclusion Similar to Olmetec,treatment with olmesartan once daily can significantly reduce ABPM in patients with mild to moderate essential hypertension.
